- Home
- OPCH vs NAMS Comparison
OPCH vs NAMS Comparison
Compare OPCH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | NAMS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OPCH | NAMS |
|---|---|---|
| Price | $23.78 | $27.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $36.57 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 32.81 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,998,202,000.00 | $22,503,000.00 |
| Revenue This Year | $7.21 | $17.96 |
| Revenue Next Year | $8.55 | $540.65 |
| P/E Ratio | $81.00 | ★ N/A |
| Revenue Growth | ★ 16.17 | N/A |
| 52 Week Low | $18.01 | $23.05 |
| 52 Week High | $36.80 | $42.21 |
Technical Indicators
Market Signals| Indicator | OPCH | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.54 | 43.73 |
| Support Level | $20.75 | $25.88 |
| Resistance Level | $24.83 | $28.97 |
| Average True Range (ATR) | 0.63 | 1.11 |
| MACD | -0.08 | 0.22 |
| Stochastic Oscillator | 46.53 | 63.78 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.